Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia
- 6 Downloads
To verify if the low estrogen regimen could condition the TSH hyperresponsivity and PRL hyporesponsivity to antidopaminergic drugs seen by us and others in patients bearing prolactinoma, the effect of ethynilestradiol treatment (50 μg/day/14 days) on TSH and PRL responses to domperidone in 6 women with tumoral hyperprolactinemia and hypoestrogenemia were studied. Estrogenic treatment was unable to modify the TSH and PRL responsiveness either to domperidone and TRH. These data do not support the hypothesis that hypoestrogenemia could cause the peculiar TSH and PRL pattern in response to antidopaminergic drugs, in patients bearing prolactinoma. Also the TRH releasable pool of TSH and PRL in these patients seems to be unaffected by estrogenic treatment.
Key-wordsEthynilestradiol TSH PRL domperidone TRH tumoral hyperprolactinemia
Unable to display preview. Download preview PDF.
- 6.Scanlon M.F., Rodriguez-Arnao M.D., McGregor A.M., Weightman D., Lewis H., Cook D.B., Gomez-Pan A., Hall R. Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin. Endocrinol. (Oxf.) 14: 133, 1981.CrossRefGoogle Scholar
- 7.Massara F., Ghigo E., Gentile L., Camanni F., Molinatti G.M. Thyrotropin and prolactin response to domperidone in subjects with physiologic or pathologic hyperprolactinemia. In: Molinatti G.M. (Ed.), A clinical problem: Microprolactinoma. Diagnosis and treatment. Excerpta Medica, Amsterdam, 1982, p. 35.Google Scholar
- 10.Erfurth E.M., Heduer P., Nilsson A. Basal and TRH stimulated serum levels of TSH in patients with hyperprolactinemia and in subjects on estrogen treatment. Acta Endocrinol. (Kbh.) 102: 173, 1983.Google Scholar